Sulpiride in tardive dyskinesia*

M Schwartz, L Moguillansky, G Lanyi, B Sharf

Abstract
The abnormal involuntary movements in tardive dyskinesia can be reduced by the dopamine antagonist drugs, phenothiazines and butyrophenones, but most cause an increase in Parkinsonian signs. Sulpiride, a benzamide derivative, and selective antagonist of D2 receptors had a significantly beneficial effect on most of 15 patients (p < 0.01). In 12 patients the improvement was marked. The reduction of abnormal movements was observed even with low doses, and it was not necessary to increase the dose of sulpiride above 600 mg daily. There were no significant side effects during the trial nor during an additional three months of treatment.

Tardive dyskinesia is an iatrogenic syndrome caused by long term use of neuroleptic drugs. The movements are often irreversible. The neurophysiological mechanism of this syndrome remains unclear. Development of dopamine receptor hypersensitivity in the striatum after prolonged neuroleptic treatment might be the cause. Tardive dyskinesia can be suppressed by postsynaptic dopaminergic receptor blockers, such as phenothiazines or butyrophenones, but this blockade may induce Parkinsonism. Otherwise, the treatment with neuroleptic drugs appears a trap: withdrawal, or reducing the dose of these drugs exacerbates the hyperkinetic movements and a patient might thus remain on neuroleptic treatment for several years, despite improvement of the psychiatric illness.

Two different dopaminergic receptors have been identified in the striatum: D1 and D2. Most neuroleptic drugs block both. Sulpiride, a benzamide derivative, is a selective antagonist of D2 receptors only. It does not block the D1 receptors, except in high concentrations. This selective action may provide an advantage in tardive dyskinesia.

In this study we have therefore evaluated the clinical efficacy of sulpiride in patients on long term neuroleptic treatment and tardive dyskinesia.

Method
Fifteen psychiatric inpatients with tardive dyskinesia (eight female, seven male) were included in the study. Their ages ranged from 37–80 years (mean 67 years). Individual patient characteristics are listed in the table. All the patients had been treated over the past five years with neuroleptic drugs and there was no change of drugs or their dose during the six months preceding or during the trial.

The duration of the neuroleptic treatment varied between 17 to 42 years (mean 28.3) and the tardive dyskinesia appeared at least several months before the start of the sulpiride treatment. All the patients were treated with anticholinergic drugs.

During the study sulpiride or placebo was added to the daily treatment. A single blind crossover placebo controlled design was used, with the patients receiving placebo or sulpiride in a randomised fashion. The initial dose of sulpiride for all the patients was 100 mg/day orally (50 mg twice a day), and increased weekly by 100 mg/day until a marked clinical improvement, without side effects, was achieved ("optimal dose"). Two weeks after reaching the optimal dose in the sulpiride group (average duration of active treatment with sulpiride was four weeks), the sulpiride was stopped and switched to placebo. At that time patients receiving placebo were switched to sulpiride. Movement patterns and quantity were scored at baseline, at two weeks and two weeks after termination of sulpiride treatment. After completion of this first phase of the study, sulpiride was reintroduced to all patients at the optimal dose for three months and then stopped. The patients were then reassessed nine to 12 months after stopping. The scores were estimated according to a rating scale of tardive dyskinesia and neurological side effects, modified from Gerlach (fig 1). Validation of

Table. Patient data, diagnosis and duration of the neuroleptic treatment

<table>
<thead>
<tr>
<th>No</th>
<th>Sex</th>
<th>Age</th>
<th>Diagnosis, duration of neuroleptic treatment years</th>
<th>Treatment* (last 5 years)**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>77</td>
<td>Schizophrenia 33</td>
<td>H, T</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>80</td>
<td>Schizophrenia 40</td>
<td>Ch</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>75</td>
<td>Schizophrenia 42</td>
<td>T, Ch, H</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>63</td>
<td>Schizophrenia 18</td>
<td>H, Ch</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>64</td>
<td>Schizophrenia 34</td>
<td>Ch, L, F</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>62</td>
<td>Schizophrenia 30</td>
<td>H, Ch, L</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>80</td>
<td>Schizophrenia 28</td>
<td>Ch, L</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>62</td>
<td>Schizophrenia 18</td>
<td>T</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>64</td>
<td>Schizophrenia 29</td>
<td>H, Ch, L</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>56</td>
<td>Schizophrenia 42</td>
<td>Ch</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>37</td>
<td>Schizophrenia 15</td>
<td>H, L</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>70</td>
<td>Schizophrenia 34</td>
<td>H, Ch, L</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>68</td>
<td>Schizophrenia 27</td>
<td>Ch, L, F</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>64</td>
<td>Schizophrenia, Epilepsy 18</td>
<td>H, L</td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>77</td>
<td>Schizophrenia 17</td>
<td>H, T, L</td>
</tr>
</tbody>
</table>

*H = haloperidol; Ch = chlorpromazine; L = levomepromazine; T = chloridiazine; F = fluphenazine.
**All patients were also treated with anticholinergic drugs.
Sulpiride in tardive dyskinesia

Results
All the patients completed the trial. Individual patient scores of treatment with sulpiride and placebo are presented in fig 2 and 3. Patients treated with sulpiride showed significantly lower tardive dyskinesia scores (p < 0.01) than during placebo treatment. In six patients (1, 2, 3, 8, 13 and 15—table), the improvement was marked; the movements diminished or stopped completely. In six other patients (6, 7, 9, 10, 11 and 14) the improvement was less marked, with movements of body and perioral regions remaining. In two of those patients (9 and 10), doses of sulpiride were not increased due to a slight increase of pre-existing Parkinsonism and in one patient (14), an increase of sulpiride over 600 mg daily, aggravated pretreatment epileptic seizures. In three patients there was no real improvement. Of those, one patient (12) showed slight Parkinsonism on 300 mg daily of sulpiride, and patients 4 and 5 did not benefit from doses of 300 to 600 mg sulpiride daily. Female patients generally responded better than males. Five of the six patients with marked improvement were females.

Side effects were observed in six patients: one patient had convulsions as mentioned above; five patients had slight Parkinsonism.

Discussion
It appears from this study that sulpiride reduced abnormal movements of mouth, trunk and limbs in patients with tardive dyskinesia. The improvement was observed even with low doses. Contrary to results in previous publications,10,11 it was not necessary to increase the dose of sulpiride above 600 mg daily. Most of the patients received 200–400 mg daily and the side effects were insignificant.

We found it surprising that in most of the patients, tardive dyskinesia disappeared after a treatment period of three months and in some, the movements did not reappear after sulpiride was stopped. Such results have not been reported before. The question arises, was it the result of loss of hypersensitivity in the dopamine receptors of the striatum or that sulpiride reinstated the normal function of the receptors in these patients?

The wide variation in clinical presentation of tardive dyskinesia is hard to explain by denervation of dopamine receptors alone. Possibly other neurotransmitters like acetylcholine, gamma-amino butyric acid (GABA), norepinephrine and serotonin are involved in this disorder.12-14

References

Figure 1. Rate scale of tardive dyskinesia and neurological side effects (modified from Gerlach's rating scale12).
Sulpiride in tardive dyskinesia.

M Schwartz, L Moguillansky, G Lanyi and B Sharf

*J Neurol Neurosurg Psychiatry* 1990 53: 800-802
doi: 10.1136/jnnp.53.9.800

Updated information and services can be found at:
http://jnnp.bmj.com/content/53/9/800

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/